Clinical-stage oncology company Black Diamond Therapeutics Inc. (BDTX) is advancing with growing visibility in biotech circles following a series of clinical and strategic updates tied to its lead candidate, silevertinib (BDTX-1535).
The company recently announced the completion of enrollment for its Phase 2 trial evaluating silevertinib in first-line (1L) patients with non-classical EGFR-mutant non-small cell lung cancer (NSCLC). A total of 43 patients have been enrolled, and data on objective response rate (ORR) and preliminary duration of response (DOR) are expected to be released in the fourth quarter of 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com